Patents by Inventor Mehmet Kemal Tur

Mehmet Kemal Tur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion protein to target and treat acute myeloid leukemia cells
    Patent number: 10072093
    Abstract: A polypeptide which binds to the surface of AML blast cells and is internalized upon binding to the AML blast cells.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: September 11, 2018
    Assignees: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., RHEINISCH-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN
    Inventors: Stefan Barth, Jenny Fitting, Mehmet Kemal Tur
  • ANTIBODIES FOR DIAGNOSIS OF ACUTE MYELOID LEUKEMIA
    Publication number: 20160304618
    Abstract: A polypeptide in particular an antibody or antibody fragment is disclosed wherein the polypeptide is corresponding to certain complementarity determining regions CDR1, CDR2 and CDR3 of a heavy chain VH and a light chain VL of an antibody as well as a compound comprising the polypeptide, its use as diagnostic agent for acute myeloid leukemia subtype M2 and a kit comprising the compound.
    Type: Application
    Filed: August 27, 2014
    Publication date: October 20, 2016
    Inventors: Stefan Barth, Mehmet Kemal Tur, Jenny Fitting
  • A NEW FUSION PROTEIN TO TARGET AND TREAT ACUTE MYLOID LEUKEMIA CELLS
    Publication number: 20160152724
    Abstract: A polypeptide which binds to the surface of AML blast cells and is internalised upon binding to the AML blast cells.
    Type: Application
    Filed: July 4, 2014
    Publication date: June 2, 2016
    Inventors: Stefan Barth, Jenny Fitting, Mehmet Kemal Tur
  • Immunokinases
    Patent number: 9045739
    Abstract: A synthetic, soluble, endogenous complex formed from at least one component A and at least one component B, whereby component A comprises a binding domain for extra-cellular surface structures that internalize upon binding of component A of said complex, and component B has a constitutive catalytic kinase activity and effects cell biosynthesis/signalling including cell death after internalization. The complex allows to influence the growth and the physiology of cells. In particular said complex, nucleic acid molecules encoding it, cells transfected or transformed with these nucleic acid molecules are usable for the preparation of medicaments for the treatment of proliferative diseases, inflammatory diseases, allergies and autoimmune diseases.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: June 2, 2015
    Assignee: Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V.
    Inventors: Stefan Barth, Mehmet Kemal Tur, Michael Stöcker, Rainer Fischer
  • Organic compounds
    Patent number: 8420787
    Abstract: The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis inflammatory bowel disease, and Hodgkin's lymphoma.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: April 16, 2013
    Assignee: Novartis AG
    Inventors: Michael Bardroff, Matthew Edwards, Mehmet Kemal Tur, Olaf Ratsch
  • Immunokinases
    Publication number: 20090136475
    Abstract: A synthetic, soluble, endogenous complex formed from at least one component A and at least one component B, whereby component A comprises a binding domain for extra-cellular surface structures that internalize upon binding of component A of said complex, and component B has a constitutive catalytic kinase activity and effects cell biosynthesis/signalling including cell death after internalization. The complex allows to influence the growth and the physiology of cells. In particular said complex, nucleic acid molecules encoding it, cells transfected or transformed with these nucleic acid molecules are usable for the preparation of medicaments for the treatment of proliferative diseases, inflammatory diseases, allergies and autoimmune diseases.
    Type: Application
    Filed: January 13, 2005
    Publication date: May 28, 2009
    Inventors: Stefan Barth, Mehmet Kemal Tur, Michael Stocker, Rainer Fischer